Information:
Error:
ID
44297
Description
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00550173
Link
https://clinicaltrials.gov/show/NCT00550173
Keywords
Versions (2)
- 7/28/18 7/28/18 -
- 9/20/21 9/20/21 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
September 20, 2021
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-Small-Cell Lung Cancer NCT00550173
Eligibility Non-Small-Cell Lung Cancer NCT00550173
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small-Cell Lung Cancer NCT00550173
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Non-Squamous Non-Small Cell Lung Carcinoma Advanced Locally | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Item
patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
boolean
C4324656 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C4288755 (UMLS CUI [2])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C4288755 (UMLS CUI [2])
Non-smoker
Item
patients must be non-smokers
boolean
C0337672 (UMLS CUI [1])
Measurable lesion Quantity
Item
patients must have at least one measurable lesion
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
ECOG performance status
Item
performance status of 0 to 2 on the eastern cooperative oncology group scale
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Quantity failed | Disease Progression | Eligibility Chemotherapy Additional
Item
patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])
C1548635 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1524062 (UMLS CUI [3,3])
C1265611 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])
C1548635 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1524062 (UMLS CUI [3,3])
Drugs, Non-Prescription
Item
patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication
boolean
C0013231 (UMLS CUI [1])
Pharmaceutical Preparations Against Epidermal Growth Factor Receptor
Item
patients who have previously received treatment with drugs against the human epidermal growth factor receptors
boolean
C0013227 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0034802 (UMLS CUI [1,3])
C0521124 (UMLS CUI [1,2])
C0034802 (UMLS CUI [1,3])
Pharmaceutical Preparations Pemetrexed Similar
Item
patients who have previously received treatment with drugs which have similar targets as pemetrexed
boolean
C0013227 (UMLS CUI [1,1])
C0210657 (UMLS CUI [1,2])
C2348205 (UMLS CUI [1,3])
C0210657 (UMLS CUI [1,2])
C2348205 (UMLS CUI [1,3])
Eye Abnormalities Surface
Item
patients who have any known significant ophthalmologic abnormalities of the surface of the eye
boolean
C0015393 (UMLS CUI [1,1])
C4321570 (UMLS CUI [1,2])
C4321570 (UMLS CUI [1,2])
Severe allergy erlotinib | Severe allergy pemetrexed
Item
patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed
boolean
C2945656 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0210657 (UMLS CUI [2,2])
C1135135 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0210657 (UMLS CUI [2,2])